Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leonard Resignation Leaves AAM Looking For New Leadership

Gaugh Steps In As Interim CEO Of US Generics And Biosimilars Association

Executive Summary

Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.

You may also be interested in...



Wave Of New Leaders Could Reshape Generics Industry

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.

In Quick Succession: Wave Of New Leaders Could Reshape Industry

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.

IGBA Names New Chair As More Leaders Join CEO Committee

The IGBA has named the AAM’s David Gaugh as its chair for the remained of 2023, following the recent departure of Jonathan Kimball. At the same time, the international generics and biosimilars association has added two recently-appointed off-patent industry CEOs to its advisory committee, representing Apotex And Viatris.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel